Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Net Income | 1.05% | -- | -- | -9.30% | |
| Total Depreciation and Amortization | -- | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 338.11% | -- | -- | -135.97% | |
| Change in Net Operating Assets | 161.28% | -- | -- | 44.70% | |
| Cash from Operations | 33.15% | -- | -- | -4.32% | |
| Capital Expenditure | 26.97% | -- | -- | 73.19% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -100.00% | -- | -- | 0.00% | |
| Cash from Investing | 26.14% | -- | -- | 73.41% | |
| Total Debt Issued | -22.62% | -- | -- | -- | |
| Total Debt Repaid | -17.82% | -- | -- | -50.75% | |
| Issuance of Common Stock | 670.00% | -- | -- | 1,900.00% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 97.01% | -- | -- | -13,500.00% | |
| Cash from Financing | 173.28% | -- | -- | -101.54% | |
| Foreign Exchange rate Adjustments | 74.88% | -- | -- | -273.78% | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 39.01% | -- | -- | -7.94% | |